KEYNOTE-024: goodbye to chemotherapy?

In the last 2 years the therapeutic landscape of non-small cell lung cancer (NSCLC) has seen a rapid shift with the introduction of immunotherapy into treatment strategy. Studies have demonstrated superior overall survival (OS) for monoclonal antibody therapy, directed against either the PD-1 receptor [nivolumab (1,2) and pembrolizumab (3)] or its ligand [PD-L1, atezolizumab (4,5)], when compared with docetaxel chemotherapy.